Hysterectomy. N99-N99 Other disorders of the genitourinary system
Conditions
Interventions
Population study Will be divided into two groups. study group(Group 1) and control group (Group 2).In study group 2 pills equal to 400 mcg misoprostol and in control Group 2 pills vitamin B6
Placebo
Sponsors
Vice President of Research Kermanshah University of Medical Sciences
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Inclusion criteria: all women undergoing abdominal hysterectomy for benign gynecologic disease and Exclusion criteria include patients who have contraindications to misoprostol, including mitral stenosis, heart disease, glaucoma, sickle cell anemia, severe hypertension, diastolic blood pressure above 100 mm /Hg, severe asthma, or known hypersensitivity to prostaglandins, known endometriosis patients with a history of pelvic or active disease, diabetes, obesity (BMI> 30), a history of previous myomectomy and previous use of GnRH agonists before surgery, patients with invasive cancer endometrial, cervical and ovarian tumors.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood loss. Timepoint: intra operative. Method of measurement: Total blood volume in the suction bottle + weight difference between dry and wet gauze. | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative hemoglobin. Timepoint: 24 hours after surgery. Method of measurement: blood test.;Degree of fever after surgery. Timepoint: 24 hours after surgery. Method of measurement: Thermometer.;Length of stay in hospital. Timepoint: From admission to exit. Method of measurement: day.;The need for blood transfusions. Timepoint: Intraoperative and postoperative. Method of measurement: On hemoglobin level and Severity of bleeding. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Tayebe Noori
Kermanshah University of Medical Sciences
Outcome results
None listed